Navigation Links
Resverlogix Notice of Conference Call & Webcast
Date:5/1/2008

TSX Exchange Symbol: RVX

CALGARY, May 1 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on May 8, 2008 at 9:00 pm MDT to provide a year-end update on both the science and the business aspects of the Company. Following the presentation there will be a live question and answer session.

The webcast can be accessed at the following link: http://services.choruscall.com/links/resverlogix0800508.html or on Resverlogix's website at: http://www.resverlogix.com.
Participants can also dial in for the conference call:

Dial information is as follows:

International Dial In: 1 604 638 5340

North America Toll Free: 1 800 319 4610

The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
7. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
8. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
9. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
10. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
11. YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to announce ... Charlottetown , PEI.  Bioenterprise has established ... ADAPT Council for the commercialization of agricultural technologies and ... with PEI ADAPT.  They have been at the heart ... decade," explains Dave Smardon , President & CEO ...
(Date:4/16/2015)... April 16, 2015  AnaptysBio, Inc., a leader ... antibodies, today announced the advancement of its ... IND-enabling studies. The Company,s anti-IL-36R therapeutic antibody, ... generalized pustular psoriasis (GPP), an orphan systemic ... is wholly owned within AnaptysBio,s proprietary antibody ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... N.J., Jan. 21 Wedgewood Pharmacy has,announced ... (Bevacizumab) to,retinal specialists and ophthalmologists who request ... Avastin,s manufacturer, Genentech,s, decision,( http://www.lucentis.com/lucentis/pdf/announcement.pdf ) to ... of January 1., Avastin is commonly ...
... 21 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... of portions of the recently completed and ... planning for 2008,and employee recognition ceremonies., ... Mr. Zhang, Director and General Manager of ...
... chocolate present risk, OAKLAND, Calif., Jan. 21 ... whether from coffee, tea, caffeinated soda or hot,chocolate ... a new study,by the Kaiser Permanente Division of ... symptoms of nausea, vomiting and caffeine,aversion that tended ...
Cached Biology Technology:Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 2Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 3Kiwa Posts Video of 2007 Annual Management Meetings 2Kiwa Posts Video of 2007 Annual Management Meetings 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... get a jump on the latest news in science and ... Research Day set for Nov. 9, 2011. The event, ... for the best and brightest graduate students to display their ... Students from Stevens Institute of Technology, Rutgers University -- Newark ...
... first DNA barcoding survey of crustaceans living on samples of ... The results suggest that the diversity of organisms living on ... "The Diversity of Coral Reefs: What Are We Missing?" was ... At depths of 26 to 39 feet, the ...
... Nov. 2In the emerging field of tissue engineering, scientists ... The ultimate goal is to create living structures that ... damaged tissue, but the manufacture of appropriately detailed scaffolds ... engineering applications confined to the research lab. Now a ...
Cached Biology News:NJIT grad students display work at 7th annual Research Day on Nov. 9 2New study reveals coral reefs may support much more biodiversity than previously thought 2Manufacturing microscale medical devices for faster tissue engineering 2Manufacturing microscale medical devices for faster tissue engineering 3
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: